Breast screening controversy and the 'mammography wars'-two sides to every story
To the Editor-Whilst the emphasis on shared decision making in breast screening of Sitt et al 1 is warmly welcomed, one struggles to visualise how this can be promoted when their overview could arguably be condensed into three major take-home messages: (1) any study critical of screening is 'controversial'; (2) risks of screening are overstated; and (3) harms of not screening are overestimated.
The "mammography wars" are predicated by the multiple ways one may analyse mammography screening studies. Estimates of the harms versus benefit "balance sheet" vary wildly depending on the approach utilised (Table) . 2, 3 Furthermore, estimates of overdiagnosis rates can range from 0% to 54%, 4 dependent on whether studies are based on modelling or cohort observation, which denominator is used, and what adjustments are made (themselves sometimes debated). Essentially, the body of evidence can be "tortured" to give almost any answer you desire. Surely no other topic in medicine can show so many ways to slice the same cake?
The most ardent supporter and passionate dissident can agree that breast screening is imperfect-arguably favourable to suppressing any component of the debate is providing a balanced view. This does not need to constitute a conciliatory back-of-the-envelope calculation-this 'third way' Hong Kong Med J 2018;24:320-1 DOI: 10.12809/hkmj187405 could manifest as the (importantly) independent United Kingdom panel report 5 which calculated that screening 233 women for 20 years can prevent one death, but three women will be overdiagnosed and overtreated.
Only when Hong Kongers are fully informed of the potential benefits and harms can they make truly informed choices.
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